Trial Profile

Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer: the Multicenter ASTRUM-005R Study

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Serplulimab (Primary) ; Antineoplastics
Indications Small cell lung cancer
Focus Therapeutic Use
Acronyms ASTRUM-005R

Most Recent Events

01 Apr 2025 New trial record
27 Mar 2025 Results (n=635, with a median follow-up of 14.9 months) presented in the Shanghai Henlius Biotech Media Release.
27 Mar 2025 According to Shanghai Henlius Biotech media release, company presented result data from this study in a poster presentation at the 2025 European Lung Cancer Congress (ELCC).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com